Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

- Company to be Featured on Oct 25, 2007 -

SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Windhover Information has chosen the company's lead compound, VIA-2291, as one of the top ten most interesting cardiovascular projects available for partnering. VIA will be featured at Windhover Information's 2nd Annual Therapeutic Area Partnerships conference and Lawrence Cohen, Ph.D., chief executive officer and president of the company, will be providing more details about VIA-2291 at the meeting on October 25 at 2 p.m. Eastern Time in Philadelphia.

Windhover Information provides critical commentary, analysis and data to the biotech, pharmaceutical, and medical device and diagnostic industries. Its editorial and research staff, including the publishers of In Vivo and Startup, have chosen the top ten best compounds for licensing in each of four disease areas based on the following criteria: size of market, history of the molecule and drug, strength of the underlying science, diversity of potential indications, overall company strength and availability of multi-partnering opportunities.

"We are honored and delighted that VIA-2291 has been identified as one of the top cardiovascular drugs by the knowledgeable editorial and research staffs of the Windhover organization," said Dr. Cohen.

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of 5-L
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... -- Investor-Edge has initiated coverage on the ... ), Insmed Inc. (NASDAQ: INSM ), BioCryst ... (NASDAQ: DYAX ), and Oncothyreon Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . On Friday, ... up 0.69%, the Dow Jones Industrial Average advanced 0.76%, ...
(Date:10/26/2014)... October 26, 2014 The report "Protective ... Application - Global Trends & Forecast to 2019", defines ... and forecasting of volume consumed and value generated. The ... KT in 2014 to 6,701.3 KT by 2019, at ... Browse 91 market data tables and 22 figures spread ...
(Date:10/25/2014)... Los Angeles, California (PRWEB) October 23, 2014 ... VDRM ), a specialty pharmaceutical company devoted to ... pursuing out-licensing partnerships in 2015. , ViaDerma has ... method, which allows for rapid mass transfer of ... into the body to provide immediate localized therapy. ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 According ... Market by Data Center Types (Colocation, Enterprise, Telecom), ... Types (Tier 1, Tier 2, Tier 3, Tier ... MarketsandMarkets, defines and segments the Data Center Construction ... and forecasting of revenues. This research report also ...
Breaking Biology Technology:Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... HILL, N.C. , May 18 Patient ... educating the marketplace on new medicines. Effectively collaborating with ... treatment options and is especially critical for socially sensitive ... the Marketplace " is a 125-page report from Best ...
... May 18 Lentigen Corporation, a biotechnology ... gene delivery technologies, announced today that it has received ... transfer (STTR) grant for a program on "Lentiviral Gene ... with Dr. R. Scott McIvor Professor, Department of Genetics, ...
... ... build an enterprise-class, cross-channel B-to-B webstore for the company’s leading Pipetman® brand of ... CloudCraze eCommerce product, the new site will allow Gilson to provide an easily ... ...
Cached Biology Technology:Educating the Marketplace Through Collaborations with Patient Advocacy Groups 2Educating the Marketplace Through Collaborations with Patient Advocacy Groups 3Lentigen Awarded Phase I STTR Grant for Hunter Syndrome 2Lentigen Awarded Phase I STTR Grant for Hunter Syndrome 3Gilson, Inc. Selects EDL Consulting's CloudCraze For Cross-Channel Webstore Expansion in Europe 2Gilson, Inc. Selects EDL Consulting's CloudCraze For Cross-Channel Webstore Expansion in Europe 3
(Date:10/29/2014)... German . ... Peter Schlögelhofer at the Max F. Perutz Laboratories (MFPL) ... of Vienna dived into the process of meiosis in ... an inversion of the standard meiotic phases. The researchers ... Nature Communications . , Meiosis is the two-step series ...
(Date:10/29/2014)... An innovative workflow reveals new research potential of the ... recently published article in the Biodiversity Data ... BOLD in tabular format and imported these into a ... Writting Tool (PWT). Data were used to study ... wasps from the Microgastrinae subfamily. , BOLD is originally ...
(Date:10/29/2014)... organisms in the living world compete with members ... in how much they invest into their competitive ... to get access to high-quality resources, while others ... of the lower-quality resources that are left over ... animal and human societies seems to fluctuate considerably ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Evolution of competitiveness 2Evolution of competitiveness 3
... is taking the world on a 25-year non-stop research expeditioninto ... team of scientists and marine engineers are completing the installation ... largest and most advanced cabled ocean observatory. Using three ... five 13-tonne nodes and more than 400 instruments and sensors ...
... are the Holy Grails of nanotechnology, but nature has ... team of scientists has taken a unique look at ... assemble into clusters that direct cell movement to select ... into how complex periodic patterns in biological systems can ...
... The restoration of a 2,000-year-old bronze sculpture of the ... understand how to prevent metal corrosion, discover the safest ... perplexing problems. That,s the conclusion of a new study ... current issue of ACS, Crystal Growth & Design ...
Cached Biology News:World's largest ocean observatory takes shape 2World's largest ocean observatory takes shape 3Spontaneous assembly 2Spontaneous assembly 3Spontaneous assembly 4
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
... Assay with SR-101 Labeled Substrates (red ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
... Leu-CMK FLISP Assay with FAM-Labeled Substrate ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
... instrument is the cycler that revolutionized ... uniformity and swappable blocks ensure consistent ... This rugged machine is more than ... for new features and upgrades as ...
Biology Products: